Clowers Michael J, Moghaddam Seyed Javad
Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Cancers (Basel). 2022 Mar 31;14(7):1785. doi: 10.3390/cancers14071785.
Worldwide, lung cancer, particularly K-ras mutant lung adenocarcinoma (KM-LUAD), is the leading cause of cancer mortality because of its high incidence and low cure rate. To treat and prevent KM-LUAD, there is an urgent unmet need for alternative strategies targeting downstream effectors of K-ras and/or its cooperating pathways. Tumor-promoting inflammation, an enabling hallmark of cancer, strongly participates in the development and progression of KM-LUAD. However, our knowledge of the dynamic inflammatory mechanisms, immunomodulatory pathways, and cell-specific molecular signals mediating K-ras-induced lung tumorigenesis is substantially deficient. Nevertheless, within this signaling complexity, an inflammatory pathway is emerging as a druggable target: signal transducer and activator of transcription 3 (STAT3). Here, we review the cell type-specific functions of STAT3 in the pathogenesis and progression of KM-LUAD that could serve as a new target for personalized preventive and therapeutic intervention for this intractable form of lung cancer.
在全球范围内,肺癌,尤其是K-ras突变型肺腺癌(KM-LUAD),因其高发病率和低治愈率,是癌症死亡的主要原因。为了治疗和预防KM-LUAD,迫切需要针对K-ras下游效应器和/或其协同通路的替代策略。肿瘤促进性炎症是癌症的一个标志性特征,它在KM-LUAD的发生和发展中起着重要作用。然而,我们对介导K-ras诱导的肺肿瘤发生的动态炎症机制、免疫调节通路和细胞特异性分子信号的了解还非常不足。尽管如此,在这种信号复杂性中,一条炎症通路正逐渐成为一个可药物靶向的靶点:信号转导和转录激活因子3(STAT3)。在这里,我们综述了STAT3在KM-LUAD发病机制和进展中的细胞类型特异性功能,这些功能可作为针对这种难治性肺癌的个性化预防和治疗干预的新靶点。